Brimonidine (Alphagan) is classified as what type of adrenergic agonist?

Brimonidine is classified as an alpha-2 adrenergic agonist, which is significant for its primary mechanism of action in managing intraocular pressure in conditions such as glaucoma. As an alpha-2 agonist, it works by stimulating receptors in the central nervous system that ultimately lead to a decrease in the production of aqueous humor and an increase in uveoscleral outflow. This mechanism helps lower intraocular pressure effectively.

In addition to its therapeutic effects, brimonidine has the ability to reduce sympathetic outflow, contributing to its efficacy in treating conditions beyond ocular hypertension. Understanding this classification is crucial for recognizing the pharmacological properties of brimonidine and its clinical applications, particularly in the context of its role in lowering intraocular pressure compared to other classes of adrenergic agonists, which have different effects and uses.